The Rho family small GTPase Rac1 has been shown to play multiple roles in cell regulation including actin cytoskeleton organization, transcriptional activation, microtubule dynamics and endocytosis. Here we report a novel role of Rac1 in regulating genomic stability and cell senescence. We observed in primary mouse embryonic fibroblasts (MEFs) that deletion of Rac1 by gene targeting, as well as expression of the constitutively active Rac1 mutant, L61Rac1, led to decreased cell growth that was associated with altered cell cycle progression at both G1/S and G2/M phases, increased apoptosis and premature senescence. The senescence induction by either loss or gain of Rac1 activity was at least in part due to an elevation of cellular reactive oxygen species (ROS).
surveillance (1) (2) (3) . Senescence can be triggered by DNA damage and/or activated oncogenes and is typically characterized by upregulation of cell cycle inhibitors such as p16 INK4a , p27
Kip and/or p53 that accompanies an irreversible G1 or G2 growth arrest (4) .
In mouse embryonic fibroblasts (MEFs), senescence relies mainly on the activated p19 ARF /p53 pathway, and it has been shown that DNA damageor oncogene-induced senescence in MEFs can be suppressed by the loss of p53 or p53 regulators (4, 5) . Thus, in addition to the role in DNA repair, apoptosis and cell cycle control, the oncogene-or DNA damage-activated p53 pathway has been proposed to be a key regulator for cell senescence (1, 2, 5) .
Rac GTPases (Rac1 , Rac2 and Rac3) are members of the Rho GTPase family that act as molecular switches cycling between an inactive GDP-bound state and an active GTP-bound state in response to a variety of extracellular stimuli (6, 7) . Rac1 and Rac3 are ubiquitously expressed while Rac2 is hematopoietic lineage-specific (6, 8, 9) . Rac1, the better characterized Rac subfamily member, can regulate unique signal pathways through engagement of specific effectors. Although Rac1 is well known for its pivotal roles in the regulation of actin cytoskeleton, adhesion and migration (6, 7) , accumulating evidence has also implicated this Rho GTPase in multiple aspects of cell proliferation including cell cycle progression and cell survival (9) (10) (11) .
For example, the constitutively active (e.g. Q61LRac1) or a fast cycling Rac1 mutant (e.g. Rac1b), as well as many of the Rac guanine nucleotide exchange factors (e.g. Tiam1 and Vav), are oncogenic in fibroblast cells and tumorigenic in mice (12) (13) (14) (15) . Microinjection of active mutants of Rac1 into quiescent Swiss 3T3 cells stimulated G1/S phase progression and DNA synthesis while the dominant negative Rac1 mutant inhibited the cell cycle. Ras and other oncoproteins such as Tiam1 require Rac1 to cause cellular transformation and tumor induction (12, 16, 17) , and loss of Rac1 activity may contribute, in part, to the cell cycle arrest caused by geranylgeranyltransferase inhibitors of the prenylation of Rho proteins (18) . Constitutively active Rac1 has also been shown to be a potent inducer of cellular reactive oxygen species (ROS 1 ) (19) (20) (21) , and Rac1 may serve as an important link between oncogenic Ras and Ras-mediated ROS activation (22) . These and other related evidence have led to the proposal that Rac1 may serve as a potential anti-cancer therapeutic target (11) .
Using a genetic approach, our laboratory has shown that the p19
Arf -p53 pathway negatively modulates Rac1 activity and regulates actin cytoskeleton, focal adhesion and cell migration mediated by Rac1 in primary mouse embryonic fibroblasts (MEFs) (23, 24) . Moreover, Rac1 may contribute to the p53-regulation of cell proliferation by modulating transcriptional and cell cycle machinery, and Rac1 hyperactivation can collaborate with p53 loss of function to promote primary cell transformation (25) . However, the mechanistic connection between Rac1 and p53 remains to be defined. Several recent reports have begun to associate Rac1 activity with cellular senescence, particularly in regulating cell morphology and actin structure in the senescence state (26, 27) . Partly due to the lack of a suitable primary cell system that allows genetic manipulation of Rac1 expression and to the non-specific and dosage-dependent mode of action of dominant negative Rac1 mutants that have previously been widely used in cell biology studies, the involvement of Rac1 in cell senescence regulation, and in cell proliferation in general, remains incompletely understood.
To better understand the role of Rac1 in cell growth regulation, we have generated the Rac1 gain of activity, L61Rac1 mutant-expressing primary MEFs by retrovirus transduction, and produced the Rac1 loss of activity, Rac1 -/-, primary MEFs from Rac1 conditionally gene targeted mice.
The examination of these primary cells allows us to determine the contribution of Rac1 activity to various cell growth properties including cell cycle progression, apoptosis and senescence that could not be easily assessed previously. We found that in addition to regulating cell cycle G1/S and G2/M phase transitions and cell survival, appropriately regulated Rac1 activity plays an important role in regulating cell senescence through the maintenance of cellular ROS level and genomic stability in the primary cells. By further examination of Rac1 gain or loss of activity cells in the p53 -/-genetic background, we demonstrate that Rac1 activity serves as a key regulator of cell senescence by a p53-dependent mechanism.
EXPERIMENTAL PROCEDURES
DNA constructs -Rac1 point mutants (N17Rac1 and L61Rac1) were generated previously (25 -/-MEFs were derived from E11.5-E13.5 old mouse embryos of the respective mice in the C57BL/6 x 129/sv genetic background (9, 25) and were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM glutamine, 0.1 mM nonessential amino acids, 55 µM ß-mercaptoethanol and 10 µg of gentamicin/ml as previously described (25, 29) . Only low passage (less than 5 passages) MEFs were used for the initiation of all described studies.
Recombinant retroviruses were produced using the Phoenix cell packaging system (28, 30) . Primary MEFs were infected with the respective retroviruses and harvested 48 to 72 hrs postinfection. The EGFP-positive cells were isolated by fluorescence-activated cell sorting (FACS). The Cre recombinase expressing adenovirus was amplified in HEK 293 cells and the supernatant was applied by serial dilution to the WT or Rac1 loxp/loxp MEFs to achieve complete Rac1 deletion in the Rac1 loxp/loxp MEFs without detectable toxicity.
To determine cell population doubling, 1x10 6 cells were plated in 100-mm tissue culture dishes and the cells were passed at the same density and quantified every three days. Such a passage protocol was reiterated until the cells reached full senescence.
To specifically knock-down Rac3 expression in MEFs, mouse Rac3 SMARTpool siRNA and control mock siRNA were obtained from Dharmacon Research Inc. (Lafayette, CO). The siRNAs were transfected into MEFs using the LipofectAMINE TM Reagent (Invitrogen) according to the manufacturer's protocol. Cells were grown for 3 days after transfection in serum-containing media and were harvested for Western blotting and ROS activity measurement.
Immunoblotting -The protein concentrations in the whole-cell lysates were normalized by the Bradford method. The ectopic expression of the dominant negative or the constitutively active form of Rac1 were probed by using an anti-HA monoclonal antibody (BD-Transduction Laboratories). p53 and phospho-p53 (Ser 15) were probed by using the antip53 and anti-phospho-p53 (Ser15) antibodies (Cell Signaling), respectively, and phospho-H2AX (Ser139) was probed by using the anti-phospho-H2AX (Ser139) (Upstate Biotechnology). The anti-β-actin antibody was obtained from Sigma. The anti-Rac1 monoclonal antibody was obtained from BD-Transduction Laboratories, and the anti-Rac3 polyclonal antibody was a generous gift from Dr. Adrienne Cox (University of North Carolina, Chapel Hill, NC).
Senescence-associated β-galactosidase activity (SA-β-gal) assay -SA-β-gal activity of the cells was detected as described (31, 32) . The percentage of positively stained cells was quantified under a phase-contrast microscope.
Cell cycle and apoptosis analysis -Cell cycle progression of the MEFs was monitored by propidium iodide (PI) labeling followed by flow cytometry analysis on a FACSCaliber machine (25) . Alternatively, cells in the S-phase expansion were captured by BrdU incorporation followed by antiBrdU immunostaining and immunofluorescence analysis . The apoptotic cells in the cell culture were detected by staining with 7AAD and allophycocyanin-conjugated Annexin V followed by flow cytometry analysis as described (9, 25) .
Immunofluorescence -For p53 or phospho-p53 (Ser15) staining, the fixed cells on cover glasses were labeled with anti-p53 monoclonal antibody (Cell Signaling) or anti-phospho-p53 (Ser15) monoclonal antibody (Cell Signaling) followed by a TRITC-conjugated anti-mouse antibody.
For phospho-H2AX (Ser139) staining, the cells were incubated with anti-phospho-H2AX (Ser139) polyclonal antibody (Upstate Biotechnology), followed by TRITC-conjugated anti-rabbit secondary antibody. Cell nuclei were labeled with DAPI for 10 min. The stained cells were mounted onto slides in Aqua-mount and viewed with a Zeiss LSM510 confocal microscopy or a Leica fluorescence microscopy equipped with the deconvolution software (Improvision, Inc.). For BrdU incorporation assay, the cells were grown on coverslips, labeled with 30 µM BrdU for 10 min., at 37ºC and fixed as previously described (24, 33) . The cells were probed for 1 hour with anti-BrdU antibody (Amersham) followed by TRITCconjugated secondary antibody.
ROS and hydrogen peroxide detections -MEF cells
were assessed for cellular ROS contents by staining with the redox-sensitive dye fluorochrome 2'-7'-dichlorofluorescein diacetate (DCFDA; Molecular Probes) as described (19, 34) . Freshly prepared DCFDA stock solution was added directly to the cell culture at a final concentration 10 µM and incubated for 30 minutes at 37ºC. The cells were washed three times with PBS and the relative levels of cytosolic ROS were detected by FACS analysis. Separately, the hydrogen peroxide concentrations in the N17Rac1, L61Rac1 and WT cells that express the EGFP marker due to prior retrovirus transduction procedures were detected using a Colorimetric Hydrogen Peroxide Kit from Assay Design, Inc., following the manufacturer's instructions.
Rac-GTP effector-domain pulldown assay -
Glutathione S-transferase fused p21-binding domain (PBD) of PAK1 was used to probe the relative Rac1-GTP and Rac3-GTP levels in the cell lysates by a GST-agarose affinity precipitation method as previously described (30) .
Karyotype Analysis -
Metaphase slides were prepared from log-phase growing MEF cells. The slides were aged at 55 ºC overnight before incubation with DAPI. Metaphase spreads were captured by using a SpectraCube ® (Applied Spectral Imaging) mounted on Olympus BX51 fluorescent microscope and the chromosome images were analyzed by using the FISHView v3.0 software (Applied Spectral Imaging). The chromosome integrity of 100 cells for each genotype were analyzed and quantified.
RESULTS

Rac1 gain or loss of activity results in impaired cell proliferation -
Wild type, Rac1 loxP/loxP
, and p53 -/-MEFs were derived from the congenic strains of mice at embryonic day 11.5-13.5 and were cultured by a well established protocol in the presence of 10% FBS (29) . To achieve a gain of Rac1 activity, wild type MEFs were transduced with retrovirus bicistronically expressing the N-terminal HA-tagged constitutively active Rac1 mutant, L61Rac1, and EGFP. The EGFP-positive cell population was isolated by FACS and used for further analysis. To obtain the Rac1 loss of activity cells, the Rac1 loxP/loxP MEFs were twice infected with a recombinant adenovirus expressing the Cre recombinase at a titer that shows no detectable toxicity in the WT MEFs (WT+Cre). Expression of L61Rac1 in transduced cells was confirmed by anti-HA Western blotting, while effective deletion of Rac1 by the adeno-Cre treatment was confirmed by anti-Rac1 Western blotting (Fig. 1A) . The Rac1 antibody appears to be highly specific toward endogenous Rac1 since it does not detect Rac2 or Rac3 in various Rac1 -/-blood lineages or Rac3 in Rac1 -/-mouse forebrain (9, 40, 41; data not shown). The cells were passaged every three days following a 3T3 subculture schedule in the standard MEF medium, and the population doublings were quantified over a 12-day period (passages 4-7). As shown in Fig. 1A , WT, WT+Cre, L61Rac1 and Rac1 -/-MEFs had a similar doubling time in the first 3 days (passage 4), but the growth rates of L61Rac1 and Rac1 -/-cells were significantly slower than that of WT or WT+Cre cells after a 9-day culturing (passage 6). The p53 -/-MEFs, as expected, showed a hyperproliferative growth rate during the course of the examination (Fig. 1A) . Further, expression of the dominant negative Rac1 mutant, N17Rac1, in WT or Rac1 The reduced proliferative potential of the cells due to Rac1 gain or loss of activity might be related to the previously characterized Rac1 function in cell cycle or apoptosis regulation (35) . To examine the involvement of Rac1 in the primary MEF cell cycle, we carried out parallel experiments by BrdU-labeling and by propidium iodide (PI) staining of the L61Rac1, wild type and Rac1
-/-cells to reveal the effect of the gain or loss of Rac1 activity on the various stages of cell cycle progression. Incubation of BrdU in the regular medium with passage 5 cells led to effective labeling of the cell nuclei of WT+Cre cells, but the L61Rac1 or the Rac1 -/-cells showed ~ 50% reduction in BrdU-positive numbers (Fig. 1B) . PI staining also revealed a significantly reduced S-phase population of the L61Rac1 cells and the Rac1 -/-cells compared with that of WT cells (Fig. 1C) , suggesting that Rac1 gain or loss of activity caused an inhibition of Sphase transition.
Interestingly, the G2/M cell population of the L61Rac1 expressing cells as well as the Rac1 deficient cells displayed a more marked increase in the PI staining profiles (Fig. 1C) , indicating that the alteration of Rac1 activity also affected the G2/M phase transition.
To investigate the effect of Rac1 gain or loss of activity on cell survival, we carried out Annexin V/7-AAD staining analysis of the MEFs under both standard and stress-induced conditions. As shown in Fig. 1D, Rac1 -/-cells were prone to spontaneous apoptosis compared to WT cells under the normal serum culture conditions, displaying a ~ 3 fold increase in apoptotic rate as we previously have shown (36) . The L61Rac1 cells also showed increased spontaneous apoptosis (~ 2 fold), albeit to a lesser extent than the Rac1 -/-cells. The apoptosis rates were enhanced by >5 fold in both Rac1 -/-and L61Rac1 MEFs when the cells were exposed for 12 hours to 300 nM staurosporine, a non-selective inhibitor of multiple protein kinases, whereas WT cells showed only a marginal increase (Fig. 1D) . The MEFs infected with either adeno-Cre or with retrovirus expressing only EGFP showed a similar apoptotic profile as the parental WT MEFs ( Fig. 1D ; data not shown), indicating the apoptotic effect of the cells was not related to adeno-Cre or retrovirus infection. These results suggest that both Rac1 gain and loss of activity, i.e. L61Rac1 expression and Rac1 gene deletion, can cause increased cell apoptosis. Taking into account the effects on the cell cycle G1/S and G2/M phase transitions (Figs.  1B & 1C) , we conclude that a balanced Rac1 activity is important for maintaining normal cell survival and cell cycle progression.
Rac1 gain or loss of activity induces premature senescence -
Although the increased cell apoptosis and cell cycle changes in the L61Rac1 and Rac1 -/-MEFs contributed to the slowed cell proliferation, these effects may only provide a partial explanation for the significant cell growth arrest noted in the later passages of these cells (Fig. 1A) . Since premature cell senescence has been associated with cultured primary cells, particularly under oncogenic stress (4,5), we next examined the cells at various passages for the cellular senescence phenotype by senescenceassociated β-galactosidase (SA-β-gal) staining. Despite the drastic different morphologies (L61Rac1 cells showed a typical large, flat "senescent" appearance while Rac1
-/-cells were thin, elongated, and spindle-shaped) ( Fig. 2A) that are attributable to the alter actin cytoskeleton structures of the cells (36) both the L61Rac1 and Rac1
-/-cells displayed high percentages of SA-β-gal staining ( Figs. 2A-2C ). The SA-β-gal positive L61Rac1 MEFs showed a similar extent of senescence (~65% SA-β-gal positive) as MEFs expressing oncogenic V12-Ras or the Rac-specific, N-terminal DH/PH module of the GEF Trio, TrioN (13), at similar passages (Fig. 2B ).
Rac1
-/-MEFs showed ~70% SA-β-gal stained cells, a significant increase compared with the WT or WT+Cre MEFs at similar passages (< 4%) (Fig. 2C) . The onset of SA-β-gal positive staining of L61Rac1 and Rac1
-/-cells occurred in the early passages (passages 3-4) and correlated with their decreased population doubling kinetics as seen in Fig. 1A (data not shown). Cells undergoing senescence may display a characteristic nuclear morphology that involves changes in the nucleolus DNA organization. In addition, the transcriptionally silent heterochromatin aggregation of senescent cells can be organized into nuclear foci (37) . As shown in Fig. 2D , L61Rac1 and Rac1 -/-cells displayed punctuated nucleolus foci similar to that of the V12-Ras or TrioN expressing cells with higher number of nuclear foci, whereas WT or WT/GFP cells showed smaller nucleoli and more uniform DAPI staining patterns viewed under a fluorescence microscope. Taken together, these data indicate that Rac1 gain or loss of activity causes premature senescence of primary MEFs.
Effect of Rac1 gain or loss of activity on cellular ROS activity that affects senescence -
Oncogenic Ras-induced premature senescence has been attributed in part to the ability of Ras to upregulate cellular ROS activity (22) , an effect that may require Rac1 activity. We initially hypothesized that the L61Rac1 cells might have elevated levels of ROS to affect cell senescence whereas the Rac1 -/-MEFs might show reduced ROS and induce senescence by an alternative mechanism. Surprisingly, staining of the Rac1 -/-MEFs by a ROSsensitive fluorophore, H 2 DCFDA, revealed a significantly increased ROS level in these cells compared with WT+Cre MEFs, and the elevated ROS level could be suppressed by treatment of the cells with a reducing agent, NAC (Fig. 3A) . Measurement of cellular H 2 O 2 activity also showed an increased level in both L61Rac1 and Rac1
-/-cells compared with WT+Cre cells, whereas similar assays of the N17Rac1 dominant negative mutant expressing cells showed that this mutant suppressed, rather than stimulated, cellular H 2 O 2 activity (Fig.  3B) . Interestingly, dominant negative N17Rac1 expression in the wild type MEFs did not induce premature senescence as judged by SA-β-gal staining (Fig. 3C ). Moreover, N17Rac1 was able to inhibit the senescence phenotype of the Rac1 -/-cells. Treatment of the cells with the reducing agent NAC led to marked reduction of the SA-β-gal positive senescent cell population in the Rac1 -/-MEFs as well as in the L61Rac1 MEFs. These data suggest that either Rac1 gain or loss of activity in the L61Rac1 or Rac1 -/-cells results in an increase of cellular ROS activity leading to senescence that is not mimicked by N17Rac1 expression.
To seek for a possible explanation of the unexpected differences between Rac1 -/-and N17Rac1 cells, we next examined expression of endogenous Rac3 and Rac activities of the Rac1 -/-and N17Rac1 expressing cells. Anti-Rac3 Western blot shows that Rac3 is indeed expressed in the MEFs (Fig. 4A) . Significantly, Rac1 deletion caused a compensatory increase of active Rac3-GTP that was not seen in WT or Rac1 -/-cells expressing N17Rac1 (Fig. 4A) . To further address if the Rac3 compensatory activity could explain the increased ROS activity in the Rac1
-/-cells, we utilized Rac3-siRNA to specifically knockdown Rac3 expression followed by ROS detection with H2DCFDA staining. Fig. 4B shows that Rac3-siRNA expression in the Rac1 loxP/loxP cells led to efficient knockdown of Rac3 protein without affecting Rac1 expression. Subsequent treatment of the cells by adeno-cre produced Rac1 -/-;Rac3-siRNA cells that are deficient in both Rac1 and Rac3. The downregulation of Rac3 effectively suppressed ROS activity in the Rac1 -/-cells (Fig. 4C) . Moreover, knocking down Rac3 expression in Rac1 -/-cells suppressed senescence phenotype (Fig. 4D ) but increased cell spontaneous apoptosis (data not shown).
Finally, forced expression of a constitutively active Rac3 mutant, V12Rac3, was able to induce ROS production and senescence in WT cells (Fig. 4E) . Taken together, these results strongly support a ROS-mediated senescence induction mechanism by both gain of Rac1 activity in the L61Rac1 cells and loss of Rac1 activity in the Rac1 -/-cells in which the ROS-mediated senescence is promoted through the compensatory elevation of Rac3 activity.
Rac1 regulates genomic stability -
A body of literature has suggested that cell senescence could be a response to ROS-mediated DNA damage (4,37). Rac1 hyperactivation has been linked to increased ROS level in cells (19) , and a recent study of mouse mammary epithelial cells also suggested a relationship of Rac1b activity with genomic stability (13). As shown above, propidium iodide staining and DNA content analysis of the L61Rac1 and Rac1 -/-cells showed a slight but significant increase in the percentage of cells carrying polyploid nuclei (≥4N) and a significant increase in accumulation of the G2/M phase of the cell cycle in both cells (Fig. 1C) , suggesting possible aberrations in chromosome segregation and/or DNA damage in these cells. To further examine a possible connection of Rac1 activity with DNA damage, we probed cell nuclei for the phosphorylation status of H2AX, an extensively used marker of DNA doublestrand-break (38 The major chromosomal abnormalities found in the Rac1 -/-cells included chromatid breaks (~15%), chromatid gaps (~20%), and ring-shaped chromosomes (~15%), whereas only ~5% and ~10% chromosomal ring like structure and chromatide breaks, were found in the WT+Cre and N17Rac1 cells, respectively, without other significant abnormalities. Since a previous report showed that high level expression of Cre recombinase could cause DNA damage and only low levels of Cre activity permit recombination without concomitant toxicity (39), we were particularly careful in selecting an appropriate titer of adeno-Cre virus in treatment of the cells. Thus, no toxicity or significant genomic instability was detectable in these experiments. These data suggest that either gain or loss of Rac1 activity can trigger genomic instability, and this effect is mediated at least in part by the aberrant cellular ROS caused by Rac1 gain or loss of activity. A balanced Rac1 activity in cells, therefore, may work as a guardian for genomic stability by maintaining intracellular ROS level in addition to cell cycle regulation.
The senescence regulation by Rac1 depends on p53 -
To investigate if the observed Rac1 regulation of DNA damage and senescence is related to p53 activation and function of the p53 pathway, we next examined the expression and activation status of p53 in Rac1 -/-, L61Rac1 and WT+Cre cells by Western blotting p53 and S15 phosphorylated p53. As shown in Fig. 6A , phospho-p53 as well as p53 levels in Rac1 -/-and L61Rac1 cells were significantly increased compared with WT+Cre cells. Western blotting also confirmed that the expression of cell cycle inhibitors, p16 and p21, were significantly increased in the Rac1 -/-and L61Rac1 cells (data not shown). To determine the contribution of the p53 pathway to Rac1-regulated cell senescence, we next generated the p53 Fig. 6B) . The complete reversal of the senescence phenotype of the Rac1 -/-and L61Rac1 cells by p53 deletion, combined with the above observations of p53 activation in the Rac1 -/-or L61Rac1 cells, demonstrates that the p53 pathway is essential for the Rac1 regulated cell senescence.
DISCUSSION
The Rac1 GTPase of the Rho family is well known to play key roles in cell cytoskeleton organization, adhesion and migration (6, 7) . In addition, Rac1 has been implicated in the regulation of cell growth through modulation of cell cycle progression and cell survival (11) . Although the detailed mechanism of Rac1-regulated cell proliferation remains to be defined, it is thought to involve at least two distinct pathways: activation of cell cycle promoting regulators such as cyclin D1 and inhibition of negative regulators of cell cycle progression such as p21
Cip1 and p27 Kip1 (6, 15, 40) . Rac1-regulated cell survival has been suggested to be through an anti-anoikis mechanism, and may also involve the transcription factor NF-kB (10) . However, partly due to the broad usage of clonal cell lines that typically carry numerous secondary genetic alterations and are immortalized, and due to the application of Rac1 dominant negative mutants that might not allow distinction of Rac1 from other related Rho family members (28) , the role of Rac1 in primary cell senescence has not been well appreciated. This function could constitute an important aspect of cell growth controlled by Rac1 that contributes to tumor surveillance.
In the present studies, by using primary MEFs expressing the constitutively active L61Rac1 or that are deficient in the Rac1 gene we are able to examine the involvement of Rac1 in the primary cell growth regulation. We show that gain or loss of Rac1 activity reduces cell S-phase transition and causes a significant accumulation of G2/M cell population, an effect distinct from previously reported S-phase promoting function by Rac1 in the immortalized clonal fibroblast cells. L61Rac1 expression or Rac1 knockout also induces primary MEF apoptosis (51) ; this effect by L61Rac1 was somewhat unexpected as a body of literature suggested it might act to promote survival rather than apoptosis (10) . The pro-apoptosis activity in MEFs of constitutive active Rac1 is consistent with our observations in a number of primary cell types including the hematopoietic stem/progenitors (41) .
Moreover, we find that Rac1 gain or loss of activity leads to premature cell senescence of primary MEFs. The combined effects of the increased apoptosis, the increased senescence and cell cycle defects may collectively explain the suppressed growth of Rac1 deficient and Rac1 active mutant expressing cells (Fig. 1) , although the population doubling curves may not intuitively reveal the extent of growth suppression suggested by cell senescence and DNA damage data (expressed as percentages of total cell population). Based on these observations we propose a possible mechanism connecting Rac1 gain or loss of activity to the senescence phenotype through elevated cellular ROS, increased DNA damage and p53 activation (Fig. 7) . Thus, it is likely that Rac1 regulation of cell proliferation involves multiple aspects of cell growth control including cell cycle S and G2/M phase transitions, survival and senescence.
Rac GTPases (Rac2 in particular) are critical components of the NADPH oxidase complex that regulate generation of reactive oxygen species and bacterial killing in neutrophils (42, 43) . A number of studies have suggested that Rac1 activation can lead to ROS induction in other cell types (13, (19) (20) (21) . Although the details of Rac1 induction of ROS remain unclear, both Rac1 and Rac2 have been shown to be able to bind directly to p67phox of the NADPH oxidase in a GTP-dependent manner, and serve as "organizers" of the p67 phox -gp91 phox interaction in the oxidase complex (21, 44) . Although Rac3 has not been tested in such a superoxide-producing system, given its high degree of homology with Rac1 and Rac2, it is likely to possess similar ability in activating various oxidase complexes. By using Rac1 and Rac3-specific antibodies we found that both Rac1 and Rac3 are expressed in the MEF cells, and Rac1 gene-targeting led to an upregulation of Rac3-GTP and cellular ROS. This increase in ROS can be suppressed by N17Rac1 expression (Figs. 3 & 4) , suggesting that loss of Rac1 can cause a compensatory upregulation of the Rac3-ROS pathway. In support of this possibility, expression of siRNA specific for Rac3 was able to knockdown Rac3 and suppressed ROS activity induced by Rac1 gene deletion. In this regard, Rac1 and Rac3 may share common effectors in ROS generation. We have previously also demonstrated up-regulation of Rac1 in hematopoietic cells deficient in Rac2 (9), suggesting physiological cross-talk between several Rac subfamily members.
It is well known that elevated cellular ROS can cause increased DNA damage and genomic instability (5).
Many mitogenic or oncogenic insults, including that by oncogenic Ras, have been shown to produce ROS to impact on mammalian genome integrity (5, 22) . We were surprised to notice that until recently little attention has been paid to a possible role of Rac1 in regulating genomic stability (13) , despite extensive evidence of its involvement in ROS production. Unlike cell cycle defect-or specific DNA repair machinery defectinduced DNA damage, ROS tends to elicit a broad spectrum of genomic insults that do not result in a specific form of genomic change. Consistent with this, Rac1
-/-or L61Rac1 cells showed multiple types of genomic abnormalities including chromatid breaks, chromatid gaps, endoreduplications and ringshaped chromosomes (39) . The karyotype analysis of chromosome M-phase spreads of the Rac1 gain and loss of activity cells, coupled with the phospho-H2AX staining, demonstrates a clear dependence of cellular DNA double strand breaks on ROS (Fig. 5 ) and provides strong evidence that Rac1 activity is a regulator of genomic stability.
Standard in vitro cell culture conditions are known to induce cell senescence by the accumulation in the number of cell doublings. This effect has previously being attributed to the genomic damage by the relatively high ROS and/or an unknown serum factor that produces potent genomic insults (5, 37) . One interesting aspect of our finding is that either extreme of Rac1 activity alteration, i.e. gain of activity introduced by the constitutively active L61Rac1 mutant or loss of Rac1 activity by gene targeting Rac1, can cause ROS-induced genomic instability that is associated with the senescence phenotype. Consistent with the notion that ROS-induced DNA damage is causal to premature senescence, NAC-(a ROS scavenger) treated Rac1 -/-or L61Rac1 cells showed significant reduction of SA-β-gal activity. More convincingly, we found that L61Rac1 expression or Rac1 deletion resulted in increased p53 activity, a likely DNA damage response, and that p53 deficiency could completely reverse the senescence phenotype in both cells.
The fact that p53 deficiency could rescue Rac1 gain or loss of activity cells from senescence provides additional evidence that Rac1 and the p53 tumor suppressor pathway are functionally linked in promoting cell transformation. The induction of a premature senescence program by the constitutively active Rac1 mutant provides an explanation for the previously observed cooperativity between active Rac1 and p53 deficiency in transformation of primary MEFs (24) . In this case, active Rac1-induced genomic instability, in addition to other possible oncogenic signals, could collaborate with the lack of a cell cycle check point control in the p53 -/-genetic background to promote cell hyperproliferation and transformation. On the other hand, the concept that loss of Rac1 might serve a similar role as Rac1 gain of activity to collaborate with p53 deficiency or cell immortality and promote growth transformation through genomic instability seems difficult to reconcile with the existing idea that Rac1 activity is required for cell growth or oncogenic Ras induced transformation (16, 17) . However, the previously documented Rac1 contributions to cell cycle progression, cell survival or growth promotion were derived mostly from immortalized cell lines, in which case genomic stability and the p53 pathway are likely compromised. Further, dominant negative Rac1, as we have shown here and in other studies (28) , has Rac1-independent functions involving other closely related Rho GTPases that could show a broad range of effects not relevant to Rac1. In support of the possibility that Rac1 loss of activity may have a detrimental effect on cell genomic integrity and could promote, rather than suppress, cell transformation, we have found that loss of Rac1 activity by gene targeting in primary MEFs could collaborate with oncogenes such as oncogenic Ras to overcome cell senescence and cause cell transformation (M. Debidda and Y. Zheng, unpublished observation). Previous gene targeting studies of the Rac1-GEF, Tiam1, showed that loss of Tiam1, although partially reducing the number of skin tumors induced by oncogenic Ras, actually cooperated with oncogenic Ras to promote a highly malignant skin tumor phenotype (12) , and Rac1 activity has been found to be reduced in some Rastransformed fibroblasts (45) .
Whether a compensatory upregulation of Rac3 in Rac1 -/-cells might contribute to these growth promoting events as we have shown here in MEFs remains to be accessed.
Induction of cell senescence by oncogenic Ras is known to require a number of possible pathways, including ROS and p38 MAPK (22, 46, 47) . Although we have shown ROS activity is needed for Rac1-mediated senescence and DNA damage, we fully expect that additional signaling components regulated by Rac1, particularly those involved in cell cycle progression, are also involved in the senescence phenotype. In addition, it remains unclear to what extent p53 is involved in Rac1-regulated cell cycle progression at either the S or G2/M phase, and whether p53 induction by Rac1 loss or gain of activity contributes to cell apoptosis. Another unresolved issue is whether the observed senescence regulation by Rac1 in primary MEFs is applicable to in vivo in cases where Rac1 hyperactivation or loss of function occurs at the organism level, since gene targeting studies of Rac1 in various blood lineages and keratinocytes have shown that Rac1 function is cell-type specific (9, (48) (49) (50) . -/-, N17Rac1 or N17Rac1;Rac1 -/-cells were subjected to the GST-PAK1 effector domain pulldown assay. The whole cell lysates as well as the GST-PAK1 co-precipitates were probed by anti-Rac1 and anti-Rac3 antibodies, respectively, to reveal the relative amounts of total Rac1 and Rac3 and the Rac1-GTP and Rac3-GTP species. The exogenous expression of N-terminally HA-tagged dominant negative N17Rac1 was examined by anti-HA Western blotting. Loading controls were provided by the parallel anti-β-actin blotting. B, lysates containing 25 µg of proteins from various cells were probed with anti-Rac1 and Rac3 antibodies. Loading controls were provided by the parallel anti-β-actin blotting. C, Rac1 
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